

**Larimar Therapeutics, Inc.  
Three Bala Plaza East, Suite 506  
Bala Cynwyd, Pennsylvania 19004**

November 18, 2022

VIA EDGAR

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549-7553

Re: Larimar Therapeutics, Inc.  
Registration Statement on Form S-3  
Filed November 10, 2022 (File No. 333-268312)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Larimar Therapeutics, Inc. (the "**Company**") hereby requests that the effective date of the Company's Registration Statement on Form S-3 (File No. 333-268312) (the "**Registration Statement**") be accelerated so that the Company's Registration Statement will become effective at 4:01 PM, Eastern Time, on November 21, 2022, or as soon thereafter as is practicable.

Please contact Jennifer L. Porter, Esq. of Troutman Pepper Hamilton Sanders LLP, counsel to the Company, at (215) 981-4339 to provide notice of effectiveness, or if you have any questions or comments concerning this request.

*[Remainder of the page intentionally left blank]*

---

Very truly yours,

**LARIMAR THERAPEUTICS, INC.**

By: /s/ Carole Ben-Maimon, M.D.

\_\_\_\_\_  
Name: Carole Ben-Maimon, M.D.

Title: President and Chief Executive Officer